Bristol Myers Squibb receives USFDA accelerated approval of Krazati in combination with Cetuximab for CRC
Second FDA approval for KRAZATI - reinforcing its potential across tumor types
Second FDA approval for KRAZATI - reinforcing its potential across tumor types
DSP-5336, an Investigational Menin and Mixed-lineage Leukemia Inhibitor, is Being Evaluated in Patients with Relapsed or Refractory Acute Leukemia
Ascentage Pharma has executed an Exclusive Option to License Global Rights to Olverembatinib worldwide other than China and a few other areas
Cipla had earlier invested € 15 million in Ethris in 2022
Detailed data from Phase 3 ECHELON-3 study demonstrate investigational ADCETRIS regimen reduced risk of death by 37 percent compared to chemotherapy alone
Higher efficacy was observed in mRNA-1283 compared to Spikevax in adults 18 years of age and older
Nadda also interacted with senior officials of the Union Health Ministry after taking charge where he was briefed about the ongoing projects
DurA Cycle is designed for large-scale commercial manufacturing of monoclonal antibodies,
Updated analysis from Memorial Sloan Kettering Cancer Center presented at ASCO 2024 has expanded to 42 patients with clinical complete response
Subscribe To Our Newsletter & Stay Updated